Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC
Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.
Previous Post
Navigating Challenges in Pediatric Dermatology Access, Addressing Disparities: Elizabeth Garcia Creighton
Next Post
Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago